anthonyyazdaniml/gliner-biomed-curated-corpus huggingface dataset:
Over 300,000 neonates worldwide die in their first month of life due to a congenital birth defect. Thanks to advancements in diagnostic technology and imaging, the field of fetal surgery was developed to treat some of these conditions in utero. Results have demonstrated improved short and long-term outcomes following surgery, especially for those fetuses diagnosed with congenital diaphragmatic hernia, lower urinary tract obstruction and spina bifida. However, over 30% of the surgical cases will have preterm labor, leading to complications related to neonatal prematurity. The cause of this surgery-induced preterm birth is unknown; however, disruption in fetal-maternal tolerance may lead to immune activation and inflammation of the maternal and fetal immune systems. Maintaining immunologic tolerance is essential during pregnancy, as a women shares only half of her genetic material with the fetus. Previous work has demonstrated that fetal surgery leads to an increase in maternal cells identified in cord blood. Animal studies have also shown that in utero intervention leads to the activation of maternal cells against fetal (paternal) antigen. Based on this previous data, it is hypothesized that surgical trauma following in utero intervention results in mixing of maternal and fetal cells leading to activation of systemic (adaptive maternal immunity) and regional (fetal placental macrophages) immune responses that disrupt fetal-maternal tolerance, which can result in preterm birth. Blood will be collected from pregnant women and their partners. Blood and placental tissue will be collected from infants that do and do not undergo in utero surgery to determine whether maternal T cells specific to fetal antigen are activated and expand after in utero intervention; and 2) to determine whether placental macrophages (Hofbauer Cells) and histology in the maternal-fetal interface exhibit increased activation and inflammation in surgical cases born preterm (\<37 weeks) compared to term. Should this exploratory study reveal activation of maternal and/or fetal immune responses following in utero surgery, modalities aimed at therapeutically suppressing these acute responses may prolong gestation, significantly benefiting newborns diagnosed with a congenital anomaly.
Every year, roughly 700 of the 750 million visits that overweight and obese patients make with primary care providers (PCPs) occur without any weight counseling. The main reasons for this are that PCPs are poorly trained to help their patients lose weight and that there are no consistently effective interventions for primary care settings. Though in-person and telephone-based weight control programs have been difficult to disseminate in primary care, online weight control programs are increasingly effective and may lend themselves to be used in these settings. Given the growing number of effective online programs, for obesity and for other conditions seen in primary care (e.g., depression, insomnia) it is important to understand whether these programs can be effective when integrated into primary care and whether they are enhanced by provider involvement. Research on the 5 A's model of primary care behavior change suggests that the most effective, yet least used feature of primary care interventions is arranging follow-up, where providers hold patients accountable to adhering to treatments and achieving specific outcomes.

The 5 A's model provides a useful framework for integrating behavior change interventions into primary care. In this model, providers ASK about weight, ADVISE patients to lose weight, ASSESS readiness to change, ASSIST the patient in making changes and ARRANGE follow-up. Unfortunately, though PCPs are uniquely positioned to ARRANGE follow-up, given their long-term relationship with the patient, and studies show that ARRANGING follow-up may be the most effective of the 5 A's, it is the least often used. In a study of 481 encounters with overweight patients, Pollak (Consultant) and colleagues observed that PCPs ARRANGED follow-up in only 5% of visits, though it was the only one of the 5 A's associated with future weight loss. Kottke and colleagues similarly observed that primary care smoking cessation interventions that included more "reinforcing sessions" with PCPs were the most effective. This is consistent with conclusions by Whitlock and colleagues that "Simply notifying patients that follow-up will occur seems to be a powerful motivating factor". These findings have been extended to online interventions, where two meta-analyses concluded that the impact of online interventions for depression and anxiety is enhanced by follow-up that includes being accountable to and supported by a human being.

The investigators have created a simple method for integrating an Internet weight control program into primary care settings, by allowing PCPs to monitor their patients' adherence and outcomes and email them pre-written, tailored follow-up messages. PCPs in the investigators' pilot work believed that this would help to overcome key barriers to helping their patients lose weight.
The aim of this study is to examine the effect of brain awareness intervention on metacognition, self-efficacy and treatment motivation in patients with alcohol and substance use disorders. It is an experimentally designed study with a randomized control group and repeated measurements (pre-test, mid-test, post-test). 77 inpatients at the Alcohol and Drug Addiction Treatment and Research Center included between April and October 2021. In addition to standard treatment, psychoeducation and counseling provided as part of the Brain Awareness Intervention for the experimental group of 39 patients. The control group of 38 patients will receive education about Being Healthy in addition to standard treatment and standard follow-up. Patients' pathological metacognitive activities, self-efficacy perceptions and treatment motivation will assessed with the Metacognition Scale-30, Self-Efficacy Scale and Treatment Motivation Questionnaire using one-way and two-way repeated measures analysis.
Patients will receive nutritional counseling by a bariatric dietitian in a routine round, aiming that they will know the post-surgery diet stages and to not develop any nutritional deficiencies.Before discharge from the hospital, patients will receive supplement and will be advised by the dietitian regarding its use (one can per day, over 3-5 intervals). Supplement contains (per 200 ml can) 20 g of protein, 250Kacl plus different micronutrient and macronutrient (Cubitan Protein, Nutricia, Netherlands).
Japanese encephalitis virus (JEV) is a neurotropic pathogen that causes lethal encephalitis. The high susceptibility and massive proliferation of JEV in neurons lead to extensive neuronal damage and inflammation within the central nervous system. Despite extensive research on JEV pathogenesis, the effect of JEV on the cellular composition and viral tropism towards distinct neuronal subtypes in the brain is still not well comprehended. To address these issues, we performed single-cell RNA sequencing (scRNA-seq) on cells isolated from the JEV-highly infected regions of mouse brain. We obtained 88,000 single cells and identified 34 clusters representing 10 major cell types. The scRNA-seq results revealed an increasing amount of activated microglia cells and infiltrating immune cells, including monocytes & macrophages, T cells, and natural killer cells, which were associated with the severity of symptoms. Additionally, we observed enhanced communication between individual cells and significant ligand-receptor pairs related to tight junctions, chemokines and antigen-presenting molecules upon JEV infection, suggesting an upregulation of endothelial permeability, inflammation and antiviral response. Moreover, we identified that Baiap2-positive neurons were highly susceptible to JEV. Our findings provide valuable clues for understanding the mechanism of JEV induced neuro-damage and inflammation as well as developing therapies for Japanese encephalitis.
Continuous glucose monitors will be fitted for 7 days, along with activity trackers and a food diary to monitor the impact of these factors on blood glucose concentrations. Participants will also complete questionnaires related to health inequalities and quality of life.
1430461 Purification of blood RESEARCH CORP 9 July 1973 [13 July 1972 11 June 1973] 32587/73 Heading A5B A method of removing serum hepatitis antigen (HAA) from blood fluids comprises (1) coupling serum hepatitis antibody to a support phase comprising carbohydrate groups to form an antibody support phase complex (BHAB) and (2) agitating BHAB with the fluid to be treated to form a complex with the antigen and (3) separating the antigen-BHAB complex from the fluid. The support phase is preferably agarose or a cellulosic material. The support phase may be activated with cyanogen bromide for coupling with the antibody. The BHAB is agitated with the fluid preferably at a temperature between 0‹C and 45‹C. Pure HAA may be produced by reacting the HAABHAB complex separated in step (3) with (a) an aqueous alkali solution having a pH in the range of 9 to 12 or (b) an aqueous solution of glycine acid salt having a pH between 2.5 and 4, and separating, e.g. by ultrafiltration, the HAA from the aqueous solution. The BHAB may be washed with neutral saline solution and subsequently with a buffer of pH between 7 and 8 and then recycled for further use. The fluid is preferably blood plasma and the method is particularly applicable to determine HAA content by radioimmunoassay techniques.
Traditionally, the treatment of anemia associated with chronic kidney disease (CKD) involves prescribing erythropoiesis-stimulating agents (ESAs) or iron preparations. The effectiveness and safety of ESAs and iron have been established. However, several clinical issues, such as hyporesponsiveness to ESAs or defective iron utilization for erythropoiesis, have been demonstrated. Recently, a new class of therapeutics for renal anemia known as hypoxia-inducible factor (HIF)/proline hydroxylase (PH) inhibitors has been developed. Several studies have reported that HIF-PH inhibitors have unique characteristics compared with those of ESAs. In particular, the use of HIF-PH inhibitors may maintain target Hb concentration in patients treated with a high dose of ESAs without increasing the dose. Furthermore, several recent studies have demonstrated that patients with CKD with defective iron utilization for erythropoiesis had a high risk of cardiovascular events or premature death. HIF-PH inhibitors increase iron transport and absorption from the gastrointestinal tract; thus, they may ameliorate defective iron utilization for erythropoiesis in patients with CKD. Conversely, several clinical problems, such as aggravation of thrombotic and embolic complications, diabetic retinal disease, and cancer, have been noted at the time of HIF-PH inhibitor administration. Recently, several pooled analyses of phase III trials have reported the non-inferiority of HIF-PH inhibitors regarding these clinical concerns compared with ESAs. The advantages and issues of anemia treatment by ESAs, iron preparations, and HIF-PH inhibitors must be fully understood. Moreover, patients with anemia and CKD should be treated by providing a physiological erythropoiesis environment that is similar to that of healthy individuals.
The present invention relates to a prescription combining Chinese medicines and western medicines for curing duodenal ulcer and gastric ulcer, which has the characteristics of obvious effect, short cycle of treatment, conspicuous effect, high cure rate, thorough treatment, low relapse rate after healing, simple making method, low cost, etc. The prescription comprises 0.8 to 1.8g of common bletilla tuber, 0.8 to 1.8g of Eucalyptus globulus Labill and 0.1 to 0.3g of furazolidone; an optimum formula comprises 1.5g of common bletilla tuber, 1.5g of Eucalyptus globulus Labill and 0.3g of furazolidone. A making method of the present invention comprises the following steps: (1) Common bletilla tuber is put in a pot, parched with low temperature until the colour of the common bletilla tuber becomes yellow, and then the common bletilla tuber is crushed and sieved; the residual residues of the common bletilla tuber are repeatedly parched with low temperature, crushed and sieved. (2)A making method of the Eucalyptus globulus Labill is the same as the making method of the common bletilla tuber. (3) The common bletilla tuber and the Eucalyptus globulus Labill which have the same weight are evenly mixed. The time and a method of taking medicines: the medicines are eaten twice every day, before breakfast in the morning and after supper in the evening with warm boiled water.
Sleep disorders are becoming increasingly common, and their distinct effects on physical and mental health require elaborate investigation. Gut dysbiosis (GD) has been reported in sleep-related disorders, but sleep apnoea is of particular significance because of its higher prevalence and chronicity. Cumulative evidence has suggested a link between sleep apnoea and GD. This review highlights the gut-brain communication axis that is mediated via commensal microbes and various microbiota-derived metabolites (e.g. short-chain fatty acids, lipopolysaccharide and trimethyl amine N-oxide), neurotransmitters (e.g. γ-aminobutyric acid, serotonin, glutamate and dopamine), immune cells and inflammatory mediators, as well as the vagus nerve and hypothalamic-pituitary-adrenal axis. This review also discusses the pathological role underpinning GD and altered gut bacterial populations in sleep apnoea and its related comorbid conditions, particularly cognitive dysfunction. In addition, the review examines the preclinical and clinical evidence, which suggests that prebiotics and probiotics may potentially be beneficial in sleep apnoea and its comorbidities through restoration of eubiosis or gut microbial homeostasis that regulates neural, metabolic and immune responses, as well as physiological barrier integrity via the gut-brain axis.
<P>PROBLEM TO BE SOLVED: To provide a drug delivery vehicle for osteoinductive proteins, that is biocompatible, readily resorbable, and not detrimental to drug activity.  <P>SOLUTION: The problem is solved by providing a composition for treating a mammal having bone defect. The composition comprises an osteogenic protein, a calcium phosphate material as a carrier, and an effective amount of an effervescent agent. A method of using the composition and a method of using the osteogenic composition to treat osteoporotic and/or osteopenic bone are also disclosed. A composition for treating the mammal having bone defect, the composition comprising an osteogenetic protein as a bioactive factor, a calcium phosphate material as a carrier, and an effective amount of an effervescent agent is also provided.  <P>COPYRIGHT: (C)2009,JPO&INPIT
Ketoconazole is a known strong inhibitor of CYP3A4. In a pharmacokinetic study, 38 healthy female subjects received ketoconazole 200 mg twice daily for 7 days, with coadministration of alosetron 1 mg on the last day. Ketoconazole increased mean alosetron plasma concentrations (AUC) by 29%. Caution should be used when alosetron and ketoconazole are administered concomitantly. Coadministration of alosetron and strong CYP3A4 inhibitors such as clarithromycin, telithromycin, protease inhibitors, voriconazole, and itraconazole has not been evaluated but should be undertaken with caution because of similar potential drug interactions. The effect of induction or inhibition of other pathways on exposure to alosetron and its metabolites is not known.
Official participation in a collegiate athletic varsity rowing team OR participation in competitive endurance athletics. Competitive endurance athletics is defined as greater than or equal to 10 hours of exercise training per week with the majority dedicated to endurance activities such as cycling, rowing, or running. Endurance athlete subjects must be able to exercise on an upright bicycle ergometer and be between the ages of 18-50.
Treatment will consist of four weeks of daily application of 20% BA ointment to the dysplastic nevi, after which it will be removed surgically and examined. A similar dysplastic nevi will be removed as a control. Four groups of patients will be enrolled. The first group will apply the ointment once a day, the second twice a day, the third three times a day, and the fourth four times a day.
PURPOSE:To obtain a dental cleaning agent in a solid state capable of washing off stain attached to the teeth without using a toothbrush. CONSTITUTION:A dental cleaning agent in a solid state comprises an elastomer- based polymer resin mixture, an abradant and a surfactant and has 60-120 hardness (JIS K6, 301 JISA method). The polymer resin mixture as a carrier for the abradant and the surfactant is a mixture of mutually slightly compatible or partially compatible polymer reins. A combination of a polymer resin having strong polarity and a polymer resin having low polarity corresponds to the polymer resin mixture and has >=1 difference in solubility parameter value between the resins. An ethylene vinyl acetate copolymer resin may be cited as the polar polymer resin and a polyolefinic resin as the polymer resin having low polarity. Common inorganic powder is used as the abradant and a nonionic surfactant is preferable as the surfactant.
The present invention relates to a novel bag type plaster which aims at solving the defects of long pasting time, easy tickle and discomfort in a pasted position, pollution, insalubrity and inconvenient use of the current plaster. The traditional Chinese medicine for treating diseases such as hyperosteogeny, etc., is composed of radix aconite, wild aconite, clematis root, sheepweed thorn, safflower, mustard seed, pepper, corydalis tuber, dahurian angelica root, menthol and borneol. The preparation technology is reasonable, and the plaster is matched with an advanced medication device. Reflected by patients who use the plaster, the traditional Chinese medicine (bag type plaster) has great medicinal effects, short pasted time (30 to 60 minutes) and good therapeutic effects. The medication device has the advantages of reasonable structural design, convenient preservation of medicinal effects, and convenient transportation and storage. The bag type plaster is instantly proportioned, mixed and used by a user, and the user can use the present invention cleanly and conveniently.
PURPOSE: To obtain a dried mixture, tablets, pills or granules containing a steroidal compound having high efficacy. CONSTITUTION: This dry pharmaceutical preparation contains a steroidal medicine having high efficiency and a vehicle capable of binding to the medicine in an amount of >=80% and having <=10% separation potential to the medicine. The vehicle includes sprayed and dried polyalcohols, granulated α-lactose hydrate or a mixture thereof. A method for producing stable tablets comprises including at least one kind of steroidal medicine each in an amount of 0.005-0.5wt.% in each tablet. The dry mixture consists essentially or 1-100 pts.wt. of at least one kind of medicine uniformly dispersed in 2,000-20,000 pts.wt. of whole vehicle.
PROBLEM TO BE SOLVED: To obtain the subject new membrane protein derived from human dendritic cell, usable as a medicine for treating and preventing various kinds of diseases and useful as a reagent for screening ligand, agonist, antagonist, etc., to the protein. SOLUTION: This membrane protein comprises an amino acid sequence of formula I or formula II. The protein is obtained by a method, etc., transforming a host with a recombinant vector containing DNA encoding the protein, culturing the transformant and producing and accumulating the transformant or isolating and purifying it from a dendritic cell such as human Langerhans cell. Furthermore, an antibody against the protein is useful as a reagent for determining the concentration of the protein in a solution to be detected and preferably obtained by a well-known method by using the protein as an antigen. The ligand can be determined by measuring, e.g. a bound amount of test compound to the protein in the case bringing the protein into contact with the test compound.
Triple Negative Breast Cancer (TNBC) is the most aggressive breast cancer subtype suffering from limited targeted treatment options. Following recent reports correlating Fibroblast growth factor-inducible 14 (Fn14) receptor overexpression in Estrogen Receptor (ER)-negative breast cancers with metastatic events, we show that Fn14 is specifically overexpressed in TNBC patients and associated with poor survival. We demonstrate that constitutive Fn14 signalling rewires the transcriptomic and epigenomic landscape of TNBC, leading to enhanced tumour growth and metastasis. We further illustrate that such mechanisms activate TNBC-specific super enhancers (SE) to drive the transcriptional activation of cancer dependency genes via chromatin looping. In particular, we uncover the SE-driven upregulation of Nicotinamide phosphoribosyltransferase (NAMPT), which promotes NAD+ and ATP metabolic reprogramming critical for filopodia formation and metastasis. Collectively, our study details the complex mechanistic link between TWEAK/Fn14 signalling and TNBC metastasis, which reveals several vulnerabilities which could be pursued for the targeted treatment of TNBC patients.